Skip to content

D&A at other companies

Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
$661K+13.6%
Medpace Holdings, Inc. logo
Medpace Holdings, Inc.MEDP
$155K-34.3%
Tenet Healthcare logo
Tenet HealthcareTHC
$229M+11.2%
Revvity logo
RevvityRVTY
Amgen logo
AmgenAMGN
Roivant Sciences logo
Roivant SciencesROIV

Segments

By segment

See full
Operating Segment$5.87M+5.3%

Other financials

Income statement

See full
Revenue$73.7M-86.4%
Operating income-$141.3M-137%
Net income-$132.7M-136%
EPS (diluted)-$0.93-134%

Balance sheet

See full
Cash & equivalents$188.5M+1.5%
Total debt$107.9M-5.6%
Total equity$614.0M-10.1%
Total assets$2.3B+44.2%

Cash flow

See full
Operating cash flow$84.4M-81.6%
CapEx$2.6M-51.6%
Free cash flow$81.9M-82.0%

Valuation

See full
Market cap$11.52B+402%
Enterprise value$11.44B+418%
P/S18.5×+14.3×

Profitability

See full
Operating margin-35.7%+63.6pp
Net margin-48.4%+240pp
FCF margin1.8%+0.9pp

Returns & leverage

See full
Return on equity-46.4%+341pp
Debt / equity0.2×0.0×
Current ratio6.2×+1.1×

Where this comes from

Reported directly by Arrowhead Research in its filing.

Tagged under the XBRL concept us-gaap:DepreciationAndAmortization.

The official record: Arrowhead Research’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Arrowhead Research's d&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Arrowhead Research's D&A?
Arrowhead Research (ARWR) reported D&A of $6.37M in Q1 2026.
How has Arrowhead Research's D&A changed year-over-year?
Arrowhead Research's D&A increased by 4.7% year-over-year, from $6.08M to $6.37M.
What is the long-term trend for Arrowhead Research's D&A?
Over 4 years (2021 to 2025), Arrowhead Research's D&A has grown at a 30.4% compound annual growth rate (CAGR), from $8.27M to $23.93M.